Thursday, 25 Apr 2019

You are here

Outcomes of Systemic Sclerosis Hospitalization

A study of inpatient systemic sclerosis (SSc) hospitalizations using the 2012–13 National Inpatient Sample database finds an inpatient mortality rate of 5%, and that infection was the most common cause of SSc hospitalizations and in-hospital death.

Researchers from Pennsylvania calculated rates of hospitalization, in-hospital mortality, LOS and hospital costs from 9731 SSc hospitalizations; a sample from an estimated 48 655 nationwide SSc hospitalizations.

Hospitalized patients were predominantly older (63.2 years), female (82.2%) and Caucasian (71.5%).

Infection was the most common cause for SSc hospitalizations (17.4%) and for those who died (32.7%).

Hospital mortality was also associated with acute renal failure (aOR = 4.3, 95% CI: 3.3, 5.60 and aspiration (aOR= 3.5, 95% CI: 2.5, 4.9).

While the median length of stay (LOS) was 4 days, this was significantly prolonged by pulmonary fibrosis, and myositis, infection, acute renal failure, acute bowel obstruction and aspiration (aOR > 2.0 with P < 0.0001).

Higher cost of hospitalization  was predicted by acute renal failure, acute bowel obstruction, and aspiration.

SSc patients are at risk for significant morbidity and mortality, especially if hospitalized with infection or other complications of SSc.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Improved Survival in Lupus

A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.

The cohort incuded 1732 SLE patients followed between 1971 and 2013. The cause of death was gleaned from death certificates, autopsy reports, hospital records or the records of the family physicians.  

EULAR 2019 Update to Lupus Management

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Mortality Risk Factors in Systemic Sclerosis

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

In addition to a multicenter prospective study, investigators performed a metanalysis on SSc standarized mortality ratios (SMR) and hazard ratios of prognosis factors.

Better Tests Ahead in Lupus

The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.

GCA Relapse Risk High with Steroids

Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.

A literature review found 34 studies (2,505 patients) from 8 RCTs of GCA patients only treated with GC.